B细胞急性淋巴细胞白血病（B-ALL）占白血病病例的约75％，在儿童和成年人中常见。近年来，疾病诊断、分层和预后方面的进展使不同亚群的ALL能够更好地被表征。尽管B-ALL完全缓解率有显著改善，但最小残留病（MRD）和复发/难治（R/R）情况下的患者的预后仍然较差。然而，诸如靶向酪氨酸激酶或CD20分子的药物、联合治疗和改进的支持性护理等新型治疗已经改变了B-ALL的治疗模式。同时，blinatumomab已经被FDA批准用于MRD阳性或R/R的B-ALL患者。Blinatumomab是一种双特异性T细胞连接因子，含有识别结域CD3和CD19，可以重定向细胞毒性T细胞溶解B细胞。接受该药物治疗的患者报道了包括长期总生存率和改善MRD阴性反应率在内的有希望的疗效。将blinatumomab添加到新的ALL方案中似乎对改善预后不佳的B-ALL患者具有潜力。然而，神经毒性和细胞因子释放综合征是blinatumomab治疗后的两种主要不良事件。本综述对blinatumomab在R/R和MRD阳性B-ALL患者中的功能和疗效进行了总结。此外，本文简要讨论了blinatumomab作为一种新型疗法在B-ALL患者中的积极和负面方面。版权所有©2023。由Elsevier España，S.L.U.出版。

B cell acute lymphoblastic leukemia-lymphoma (B-ALL) accounts for approximately 75% of ALL cases and is observed in children and adults. Recent advances in disease diagnosis, stratification and prognostication have led to a better characterization of different subgroups of ALL. Notwithstanding the significant improvement in the complete remission rate of B-ALL, patients with minimal residual disease (MRD) and relapsed/refractory (R/R) settings suffer from poor outcomes.However, novel therapies, such as agents targeting tyrosine kinases or the CD20 molecule, combination therapies and improved supportive care, have changed the treatment landscape of B-ALL.Meanwhile, blinatumomab has been FDA-approved for MRD-positive or R/R B-ALL patients. Blinatumomab is a bispecific T cell engager containing the CD3 and CD19 that recognize domains redirecting cytotoxic T cells to lyse B cells. Promising outcomes, including long-term overall survival and improved MRD-negative response rates, have been reported in patients who received this drug. Adding blinatumomab to new ALL regimens seems promising for achieving better outcomes in poor prognosis B-ALL patients. Nevertheless, the neurotoxicity and cytokine release syndrome are the two major adverse events following the blinatumomab therapy.This review summarizes the function and effectiveness of blinatumomab in R/R and MRD positive B-ALL patients. Furthermore, blinatumomab's positive and negative aspects as a novel therapy for B-ALL patients have been briefly discussed.Copyright © 2023. Published by Elsevier España, S.L.U.